Simvastatin augmentation for recent-onset psychotic disorder: A study protocol

Marieke J H Begemann, Maya J L Schutte, Margot I E Slot, Janine Doorduin, P Roberto Bakker, Neeltje E M van Haren, Iris E C Sommer, Marieke J H Begemann, Maya J L Schutte, Margot I E Slot, Janine Doorduin, P Roberto Bakker, Neeltje E M van Haren, Iris E C Sommer

Abstract

Keywords: Anti-inflammatory; MRI; Psychosis; Schizophrenia spectrum disorders; Simvastatin; Treatment.

References

    1. Aas M., Dazzan P., Mondelli V., Melle I., Murray R.M., Pariante C.M. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front. Psychol. 2014;4:182.
    1. Addington D., Addington J., Matincka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale for Schizophrenics. Br. J. Psychiatry. 1993;163(Suppl. 22):39–44.
    1. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry. 1992;49(8):615–623.
    1. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry. 2011;70(7):672–679.
    1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676.
    1. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry. 2011;168:1303–1310.
    1. Brown A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 2011;93(1):23–58.
    1. Cahn W., Hulshoff Pol H.E., Lems E.B.T.E., Van Haren N.E.M., Schnack H.G., Van der Linden J.A. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry. 2002;59(11):1002–1010.
    1. Bernstein D.P., Stein J.A., Newcomb M.D., Walker E., Pogge D., Ahluvalia T. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003;27:169–190.
    1. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry. 2010;167:261–280.
    1. Chataway J., Schuerer N., Alsanousi A., Chan D., MacManus D., Hunter K. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;9936:2213–2221.
    1. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 2012;134:83–88.
    1. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007;93:261–265.
    1. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009;50:1801–1807.
    1. Fillman S.G., Sinclair D., Fung S.J., Webster M.J., Weickert C.S. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry. 2014;4 e365.
    1. Gerlach J., Korsgaard S., Clemmesen P., Lund Lauersen A.M., Magelund G., Noring U. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993;87:244–252.
    1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752.
    1. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005;150:115–121.
    1. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF) Br. J. Psychiatry. 1995;166:654–659.
    1. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P.M. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097.
    1. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276.
    1. Keefe R.S.E., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004;68:283–297.
    1. Knight J.G., Menkes D.B., Highton J., Adams D.D. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol. Psychiatry. 2007;12:424–431.
    1. Laan W., Selten J.P., Grobbee D.E., Smeets H., Kahn R.S., Burger H. Non-steroidal anti-inflammatory drugs and the risk of psychosis. Eur. Neuropsychopharmacol. 2007;17:309–311.
    1. Laan W., Smeets H., de Wit N.J., Kahn R.S., Grobbee D.E., Burger H. Glucocorticosteroids associated with a decreased risk of psychosis. J. Clin. Psychopharmacol. 2009;29:288–290.
    1. Meyer U., Schwarz M.J., Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 2011;132:96–110.
    1. O'Donnell P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur. J. Neurosci. 2012;35:1866–1870.
    1. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007;64:1123–1131.
    1. Schwarz E., Guest P.C., Steiner J., Bogerts B., Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry. 2012;2 e82.
    1. Sierra S., Ramos M.C., Molina P., Esteo C., Vázquez J.A., Burgos J.S. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J. Alzheimers Dis. 2011;23:307–318.
    1. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–747.
    1. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 2010;122:1–23.
    1. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007;33:729–736.
    1. Van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry. 2008;64:820–822.
    1. Van Haren N.E.M., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry. 2008;63:106–113.
    1. Van Haren N.E.M., Schnack H.G., Cahn W., Van den Heuvel M.P., Lepage C., Collins L. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry. 2011;68:871.
    1. Van Harten P.N., Matroos G.E., Hoek H.W., Kahn R.S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr. Res. 1996;19:195–203.
    1. Sommer I.E., van Westrhenen R., Begemann M.J.H., de Witte L.D., Leucht S., Kahn R.S. Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. Schizophr. Bull. 2014;40(1):181–191.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren